前收市價 | 8.05 |
開市 | 8.25 |
買盤 | 8.30 x 400 |
賣出價 | 8.36 x 1100 |
今日波幅 | 8.14 - 8.49 |
52 週波幅 | 4.97 - 15.74 |
成交量 | |
平均成交量 | 5,557,346 |
市值 | 2.241B |
Beta 值 (5 年,每月) | 0.82 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.63 |
業績公佈日 | 2024年8月06日 - 2024年8月12日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 11.57 |
The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.